TREML2 enhances sensitivity of acute myeloid leukemia cells to chemotherapy by inhibiting the NF-κB/CXCL10 pathway
The triggering receptors expressed on myeloid cells (TREMs) family of cell surface receptors are mainly expressed by myeloid cells. The expression profile of TREM-like 2 (TREML2), a TREM family member, in patients with acute myeloid leukemia (AML) is unknown. In this study, we aimed to elucidate the...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health
2025-06-01
|
| Series: | Blood Science |
| Online Access: | http://journals.lww.com/10.1097/BS9.0000000000000223 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849393686252617728 |
|---|---|
| author | Xin Zhang Shuheng Yan Xuehong Zhang Dan Huang Jiayin Zhou Xiaoting Song Yuchao Hao Xijia Wang Jinsong Yan |
| author_facet | Xin Zhang Shuheng Yan Xuehong Zhang Dan Huang Jiayin Zhou Xiaoting Song Yuchao Hao Xijia Wang Jinsong Yan |
| author_sort | Xin Zhang |
| collection | DOAJ |
| description | The triggering receptors expressed on myeloid cells (TREMs) family of cell surface receptors are mainly expressed by myeloid cells. The expression profile of TREM-like 2 (TREML2), a TREM family member, in patients with acute myeloid leukemia (AML) is unknown. In this study, we aimed to elucidate the role of TREML2 in the development of AML. We analyzed the TREML2 expression profile in patients with AML. TREML2 was expressed at lower levels in patients with AML than in healthy individuals. The partial remission (PR) + no remission (NR) group showed lower TREML2 expression levels and a poorer chemotherapy response than that observed in the complete remission group. Overall survival was significantly shorter in the group with low TREML2 expression levels than in the group with high TREML2 expression levels. TREML2 inhibited the proliferation of AML cells and enhanced the sensitivity of AML cells to doxorubicin. Mechanistically, TREML2 reduced C-X-C motif chemokine ligand 10 expression levels by inhibiting the nuclear factor kappa B pathway. Taken together, we demonstrate that TREML2 has diagnostic value as a potential indicator of AML and that upregulation of TREML2 may be a new strategy to overcome doxorubicin resistance for AML treatment. |
| format | Article |
| id | doaj-art-ffaeb0dd38084686b2b0942e2a853d87 |
| institution | Kabale University |
| issn | 2543-6368 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wolters Kluwer Health |
| record_format | Article |
| series | Blood Science |
| spelling | doaj-art-ffaeb0dd38084686b2b0942e2a853d872025-08-20T03:40:21ZengWolters Kluwer HealthBlood Science2543-63682025-06-0172e0022310.1097/BS9.0000000000000223202506000-00003TREML2 enhances sensitivity of acute myeloid leukemia cells to chemotherapy by inhibiting the NF-κB/CXCL10 pathwayXin Zhang0Shuheng Yan1Xuehong Zhang2Dan Huang3Jiayin Zhou4Xiaoting Song5Yuchao Hao6Xijia Wang7Jinsong Yan8a Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Key Laboratory of Hematology, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian, Chinab University of California, Davis, College of Biological Science, 1 Shields Ave, Davis, CA 95616, United Statesc Center of Genome and Personalized Medicine, Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning 116044, Chinaa Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Key Laboratory of Hematology, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian, Chinaa Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Key Laboratory of Hematology, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian, Chinaa Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Key Laboratory of Hematology, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian, Chinaa Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Key Laboratory of Hematology, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian, Chinaa Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Key Laboratory of Hematology, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian, Chinaa Department of Hematology, Liaoning Medical Center for Hematopoietic Stem Cell Transplantation, Liaoning Key Laboratory of Hematopoietic Stem Cell Transplantation and Translational Medicine, Blood Stem Cell Transplantation Institute, Dalian Key Laboratory of Hematology, Diamond Bay Institute of Hematology, the Second Hospital of Dalian Medical University, Dalian, ChinaThe triggering receptors expressed on myeloid cells (TREMs) family of cell surface receptors are mainly expressed by myeloid cells. The expression profile of TREM-like 2 (TREML2), a TREM family member, in patients with acute myeloid leukemia (AML) is unknown. In this study, we aimed to elucidate the role of TREML2 in the development of AML. We analyzed the TREML2 expression profile in patients with AML. TREML2 was expressed at lower levels in patients with AML than in healthy individuals. The partial remission (PR) + no remission (NR) group showed lower TREML2 expression levels and a poorer chemotherapy response than that observed in the complete remission group. Overall survival was significantly shorter in the group with low TREML2 expression levels than in the group with high TREML2 expression levels. TREML2 inhibited the proliferation of AML cells and enhanced the sensitivity of AML cells to doxorubicin. Mechanistically, TREML2 reduced C-X-C motif chemokine ligand 10 expression levels by inhibiting the nuclear factor kappa B pathway. Taken together, we demonstrate that TREML2 has diagnostic value as a potential indicator of AML and that upregulation of TREML2 may be a new strategy to overcome doxorubicin resistance for AML treatment.http://journals.lww.com/10.1097/BS9.0000000000000223 |
| spellingShingle | Xin Zhang Shuheng Yan Xuehong Zhang Dan Huang Jiayin Zhou Xiaoting Song Yuchao Hao Xijia Wang Jinsong Yan TREML2 enhances sensitivity of acute myeloid leukemia cells to chemotherapy by inhibiting the NF-κB/CXCL10 pathway Blood Science |
| title | TREML2 enhances sensitivity of acute myeloid leukemia cells to chemotherapy by inhibiting the NF-κB/CXCL10 pathway |
| title_full | TREML2 enhances sensitivity of acute myeloid leukemia cells to chemotherapy by inhibiting the NF-κB/CXCL10 pathway |
| title_fullStr | TREML2 enhances sensitivity of acute myeloid leukemia cells to chemotherapy by inhibiting the NF-κB/CXCL10 pathway |
| title_full_unstemmed | TREML2 enhances sensitivity of acute myeloid leukemia cells to chemotherapy by inhibiting the NF-κB/CXCL10 pathway |
| title_short | TREML2 enhances sensitivity of acute myeloid leukemia cells to chemotherapy by inhibiting the NF-κB/CXCL10 pathway |
| title_sort | treml2 enhances sensitivity of acute myeloid leukemia cells to chemotherapy by inhibiting the nf κb cxcl10 pathway |
| url | http://journals.lww.com/10.1097/BS9.0000000000000223 |
| work_keys_str_mv | AT xinzhang treml2enhancessensitivityofacutemyeloidleukemiacellstochemotherapybyinhibitingthenfkbcxcl10pathway AT shuhengyan treml2enhancessensitivityofacutemyeloidleukemiacellstochemotherapybyinhibitingthenfkbcxcl10pathway AT xuehongzhang treml2enhancessensitivityofacutemyeloidleukemiacellstochemotherapybyinhibitingthenfkbcxcl10pathway AT danhuang treml2enhancessensitivityofacutemyeloidleukemiacellstochemotherapybyinhibitingthenfkbcxcl10pathway AT jiayinzhou treml2enhancessensitivityofacutemyeloidleukemiacellstochemotherapybyinhibitingthenfkbcxcl10pathway AT xiaotingsong treml2enhancessensitivityofacutemyeloidleukemiacellstochemotherapybyinhibitingthenfkbcxcl10pathway AT yuchaohao treml2enhancessensitivityofacutemyeloidleukemiacellstochemotherapybyinhibitingthenfkbcxcl10pathway AT xijiawang treml2enhancessensitivityofacutemyeloidleukemiacellstochemotherapybyinhibitingthenfkbcxcl10pathway AT jinsongyan treml2enhancessensitivityofacutemyeloidleukemiacellstochemotherapybyinhibitingthenfkbcxcl10pathway |